Loading
Natco Pharma Limited Stock: price and insider trades · India
1 insider bought €79k of shares over the last 90 days, the latest by NEELIMA SITA NANNAPANENI, filed 16 Oct 2026.
Insider Decl.
98
Thresholds
n/a
Buy Volume
€462,017
15 ops. · all time
Sell Volume
€8M
47 ops. · all time
Who traded when
BuySaleSatya Vani Nannapaneni3 sales
Sanjay Nannapaneni2 sales
Tummala Rahul2 sales
Lakshminarayana Bolisetty1 sale
Natsoft Information Systems Private Limited1 sale
Neelima Sita Nannapaneni1 buy
+5 other insiders
Since the insiders bought
- -8.7%Entry ₹924.20 · Close at T+90 ₹844.25
- +69.0%Entry ₹563.35 · Close at T+365 ₹952.05
- +62.4%Entry ₹533.05 · Close at T+365 ₹865.80
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate Natco Pharma Limited Hold (neutral), based on 9 analysts. Average price target: ₹1,004.44.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 875 of 26,280 companies
81.4
score / 100
Value76
Quality87
FCF yld9.5%
Earn yld9.7%
EV/EBITDA8.9x
ROE17%
Gross mgn77%
Net mgn35%
Debt/EBITDA0.4x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2026FY ended March 2026 · cache
₹782.20
Analyst consensus
9 analystsHold
₹712.00Target ₹1,004.44(+28%)₹1,180.00
Income statement
Revenue₹40.4B
Gross profit₹31.2B77% margin
EBITDA₹17.2B43% margin
Net income₹14.2B32.8% margin
Valuation
PER (trailing)12.3x
PER (forward)16.5x
P/Book1.5x
Beta0.15
Balance sheet & cash
Market cap₹143.9B
Total debt₹7.1B
Free Cash Flow₹13.8B
Debt / Equity8%
Profitability & ownership
ROE16.9%
ROA7.8%
% insiders50.9%
% institutions13.3%
Last declaration on 16 October 2026
Declarations98 total
48,439 shares@ ₹10.000.0003% mcap1.2% of flowAny other instrumentOff MarketSEBI:b315e019707979480de03e00c9699b54f8cf7e8b
116,911 shares@ ₹10.000.0008% mcap35.1% of flowAny other instrumentOff MarketSEBI:b5a24ec54c3410966122910cf477439eb8eb913e
135,755 shares@ ₹10.000.0009% mcap19.3% of flowAny other instrumentOff MarketSEBI:61cd74e93bbc01f475a7a45dd3f599bb5e30feb1
14,285 shares@ ₹10.000.0001% mcap32.4% of flowAny other instrumentOff MarketSEBI:e38e1334a5ac9d6efd9ea4d859a4824244a443c7
17,943 shares@ ₹10.000.0001% mcap0.7% of flowAny other instrumentOff MarketSEBI:5600e22d8f00af2675e2711b51380be122420e45
1,000,000 shares@ ₹10.000.0069% mcap45.3% of flowAny other instrumentOff MarketSEBI:a081154994ec44bdf94c798306b982882f896e39
319,048 shares@ ₹10.000.0022% mcap100.0% of flowAny other instrumentOff MarketSEBI:b65d7bb88c21d7fd3f743c74e726e332ea7c23bd
237,963 shares@ ₹35.500.0058% mcap100.0% of flowAny other instrumentMarket PurchaseSEBI:faa301d1b986dafc4c0e3860355cfd0aea9cae37
Canonical exit: 14 Jan 2027 (T+90)
850,000 shares-CreationSEBI:8069746ab206319d9bc4b457cca711e95fe9bf59
566,666 shares@ ₹10.000.0039% mcap100.0% of flowAny other instrumentOff MarketSEBI:21154ba2b7f192b71afb3c75da543372b423faf5
14,884 shares@ ₹10.000.0001% mcap0.4% of flowAny other instrumentOff MarketSEBI:253af144e4d8756ae4b648808d7e9db3c31bcfc8
215,384 shares@ ₹10.000.0015% mcap100.0% of flowAny other instrumentOff MarketSEBI:4bcdc882e7c156843b39e2263b908cf6a0c5b12c
1,200,000 shares@ ₹10.000.0083% mcap44.1% of flowAny other instrumentOff MarketSEBI:4a742ec4b63b26fc175ec2ad2e47e74405faf160
57,142 shares@ ₹10.000.0004% mcap100.0% of flowAny other instrumentOff MarketSEBI:96c01a61513c698727f55d7d1dd313483c79a038
267,656 shares@ ₹34.400.0064% mcap33.9% of flowAny other instrumentMarket SaleSEBI:cc32434ae1e0c6c4e3f5ebf4b4c0f6feb299d952
333,333 shares@ ₹32.500.0075% mcap89.8% of flowAny other instrumentMarket SaleSEBI:985aa7f96cbbaac94d9fe60eb2971916a9f2c9f8
1,200,000 shares@ ₹32.000.027% mcap99.6% of flowAny other instrumentMarket SaleSEBI:0dd082c39dc1a551eac25121665ea6ce7301c9f1
598,773 shares@ ₹10.000.0041% mcap22.0% of flowAny other instrumentOff MarketSEBI:a15be81684f849bf181c944b002211ee8f871255
122,794 shares@ ₹10.000.0008% mcap10.2% of flowAny other instrumentOff MarketSEBI:ac621da96791cc955522b97bea76c983b21fc9a0
29,715 shares@ ₹10.000.0002% mcap100.0% of flowAny other instrumentOff MarketSEBI:411d2773128f7cbd14954a6208989ec89151cdfc
850,000 shares@ ₹789.400.47% mcap100.0% of flowEquityPledge CreationSEBI:8c3defd23f8f9f7ef2e95fff2e868d238a624f4d
50,000 shares0EquityGiftSEBI:11857c7fc4889db2a2f9d24a2cf794bd54708087
70,000 shares@ ₹1,017.30530.045% mcap46.3% of flowEquity SharesSEBI:274dc5941df2918e536d89fc2bfcd269e582cd13
45,000 shares@ ₹1,001.3310.028% mcap56.1% of flowEquity SharesSEBI:e6cac393a77a52cae1534ede84b97186a637e9b0
100,000 shares@ ₹803.052153.7% of flowEquity SharesSEBI:b08d1b8e9605bade4516a11dd1e0d4ec399a5bbf
25 of 98 declarations
About Natco Pharma Limited
Natco Pharma Limited, an Indian healthcare company valued at INR 143.9 billion, is held 50.9% by its filers, many of them tied to the promoter group, the Nannapaneni family and its companies. Of 98 filings published between June 21, 2021 and October 16, 2026, sales dominate: 47 sales worth EUR 7.7 million (median EUR 38,927) against 15 purchases worth EUR 462,017 (median EUR 3,512), so purchases are 24%.
The largest sale is Vidyadhari Tummala's, EUR 1,174,694 on August 19, 2024. Sanjay Nannapaneni, of the promoter group, follows with EUR 771,091 on September 29, 2025 and EUR 664,260 on March 9, 2026. The purchases are small: EUR 120,735 for Konakanchi Durga Prasad on June 21, 2021, EUR 117,129 for Natsoft Information Systemps PVT Ltd on December 1, 2022, and EUR 79,133 for Neelima Sita Nannapaneni on October 16, 2026. From August 20, 2021 to August 24, 2021, 4 filers bought for EUR 18,055.
Read moreShow less
The record also holds 26 filings of another kind and 10 grants. The annual volume is 10 in 2021, 23 in 2024, 9 in 2025 and 24 in 2026, and the last twelve months hold 24 filings, of which 5 sales and 1 purchase. They come out a median of 1 day after the trade. For 14 purchases, the stored 90-day result has a median of -9.4%, with 43% positive outcomes (stored past results, not a forecast).
